Press Releases

State of Minnesota Selects Truveris to Help Optimize Its Pharmacy Benefits Program

Program performance and pharmacy cost containment manager Truveris recently announced that the company has been selected as the exclusive oversight and procurement partner for the State of Minnesota. Together they will conduct a full reverse-auction process to guarantee the state’s pharmacy benefit needs are given superior contract terms and pricing. Truveris creates honest and fast-paced PBM marketplaces through its patented reverse-auction technology truBid®. This process pushes for notable price reductions on pharmaceutical pricing. Truveris provides a consistent outcome customized for each unique organization by performing a...

Aetion Acquires Synthetic Data Trailblazer Replica Analytics

Regulatory-grade real-world evidence technology provider Aetion recently announced its acquisition of Replica Analytics. Replica Analytics is well known for creating synthetic health data through artificial intelligence programs. Replica will be able to help Aetion through its ability to preserve the utility of source data, thanks to its AI technology generating synthetic privacy-protected copies of real-world data. This will help Aetion improve its knowledge regarding safety, higher standards of care, and treatment pathways. Aetion Co-Founder and President Dr. Jeremy Rassen explained why he’s confident about the acquisition...

M2GEN Announces Collaboration with Microsoft to Advance Bioinformatics Solutions for Oncology

Bioinformatics company M2GEN announced a partnership with Microsoft in a move to improve and expand its data-driven solutions for research, discovery, and development of oncology therapies. The collaboration will combine M2GEN’s clinico-genomics database with Microsoft’s healthcare technologies to expand the possibilities of future cancer therapeutics. High-quality data collection, healthcare expertise, and technological innovation are all necessary parts of unlocking the full potential of advanced analytics, big data, and machine learning. M2GEN’s position as the technological hub of the Oncology Research Information Exchange Network® puts the company...

Be The Match BioTherapies® and Vineti collaborate to develop innovative, integrated supply chain management solutions for cell and gene therapies

Be The Match BioTherapies® and Vineti announced a collaboration to create streamlined solutions that alleviate supply chain management difficulties related to cell and gene therapies. The collaboration is non-exclusive and is expected to unite the industry’s top workflow programs: Vineti’s Personalized Therapy Management® platform and Be The Match BioTherapies’ cellular therapy supply chain management services. Vineti offers a commercial cloud-based platform to make it easier for patients to access life-saving gene and cell therapies. Be The Match BioTherapies is known for its unique customizable cell and...

European Medicines Agency Selects Aetion to Support Safety and Efficacy Research in Europe

Aetion has been selected by the European Medicines Agency to support the agency’s Quality, Efficacy, and Safety Studies on Medicines. Aetion is a health care analytics company, working to provide real-world evidence for regulators, manufacturers, and purchasers of medical treatments and technologies. The company was founded by Harvard Medical School faculty members and uses its Evidence Platform® to analyze data and produce honest scientific answers about value, safety, and efficacy. Aetion will perform pharmacoepidemiologic research for the European Medicines Agency and generate real-world-evidence to aid...

Biopharma Industry Leaders Ian Read and Clive Meanwell Join Saama Board of Directors

The Saama Board of Directors recently gained some highly respected leaders in Ian Read, former CEO and executive chairman of Pfizer, and Clive Meanwell, former CEO and founder of The Medicines Company. This news was revealed after a $430 million strategic investment in Saama by Carlyle and co-investors including McKesson Ventures, Amgen Ventures, Population Health Partners, Merck Global Health Innovation Fund, Northpond Ventures, Intermountain Ventures, and Pfizer Ventures. “It’s an honor to join Saama’s Board of Directors and the industry experts who comprise it,” Read said...

Survey Says Moms Want In-Person Care With a Side of Digital Health

Digital health company Xealth announced a recent survey examining new mothers and their expectations for digital health in comparison with the healthcare services they received. The survey was conducted among over 1,000 new or expectant mothers, with 57 percent of them showing a more favorable opinion of digital health since the beginning of the pandemic. The study also found that telehealth appointments have increased by 540 percent among respondents, although 83 percent still had in-person visits with their doctor. Price transparency matched least with patient expectations,...

Hims & Hers Unveils Mobile Platform For Their Over 500,000 Subscription Members

Hims & Hers announced plans to provide a further encompassing and personalized care experience with the launch of its mobile application. The app is expected to be available for the company’s more than 500,000 subscription members within the coming weeks. Hims & Hers Co-founder and CEO Andrew Dudum detailed the project, stating that the unveiling “marks one of the most important announcements in our company’s history as we continue toward our goal of fundamentally reshaping what it means to access and experience great modern healthcare.” Dudum...

Clinical Ink Acquires Digital Artefacts

Global clinical trial data and technology company Clinical Ink has announced its acquisition of Digital Artefacts, a digital technology company that specializes in data capture for complex cognitive, behavioral, and physiological research. “Data derived from Digital Artefacts can now increase the richness of our partners’ study data through the convergence of passive and active digital assessments,” said Clinical Ink CEO Ed Seguine. “Their wearables and sensors acumen provides instrumented data collection that complements our existing products and solutions.” The combination of the two companies provides other benefits...

Koneksa Broadens Multi-Year CNS Research Collaboration with Sanofi

Digital Biomarker company Koneksa announced an extension to its collaboration with Sanofi in central nervous system clinical trials. Sanofi is one of the world’s top biopharmaceutical companies, and Koneksa CEO Chris Benko expressed enthusiasm for the extension: “We’re proud that our long-term partnership has enabled Sanofi’s deployment of digital measures across multiple therapeutic areas and modalities.” He also noted continued collaboration with Sanofi will open an opportunity to study new treatment options for neurological diseases like multiple sclerosis. Specifically, Koneksa’s work with Safoni will benefit research...